

25 January 2023

## Intra-Vitreous Injections or Implants

I would greatly appreciate if you could answer the following questions:

1. How many of the following intra-vitreous injections/implants has your Trust administered in the four-month period from September to December 2022:

|                        |      |
|------------------------|------|
| Aflibercept            | 3914 |
| Bevacizumab            | 6    |
| Brolucizumab           | 0    |
| Dexamethasone          | 41   |
| Faricimab              | 0    |
| Ranibizumab – Lucentis | 1388 |
| Ranibizumab – Ongavia  | 0    |

2. Please provide the number of injections/implants by eye condition for the four-month period from September to December 2022.

| Treatment              | Eye Conditions                              |                               |                              |
|------------------------|---|-------------------------------|------------------------------|
|                        | Wet Age-Related Macular Degeneration (wAMD) | Diabetic Macular Oedema (DMO) | Retinal Vein Occlusion (RVO) |
| Aflibercept            | 2969  | 414                           | 531                          |
| Bevacizumab            | 6   | 0                             | 0                            |
| Brolucizumab           | 0   | 0                             | 0                            |
| Dexamethasone          | 21  | 4                             | 16                           |
| Faricimab              | 0   | 0                             | 0                            |
| Ranibizumab - Lucentis | 932   | 314                           | 142                          |
| Ranibizumab - Ongavia  | 0   | 0                             | 0                            |